Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca PLC reports that Vanguard Capital Management beneficially owned 77,965,099 shares of Common Stock, representing 5.02% of the class as of 03/31/2026. The filing states Vanguard exercises sole voting power over 32,924,957 shares and sole dispositive power over 77,965,099 shares, and notes these holdings reflect positions held on behalf of Vanguard funds and managed accounts.
AstraZeneca reports that the US FDA has approved Breztri Aerosphere as the first and only fixed‑dose triple maintenance therapy for asthma in patients aged 12 and older. Breztri, already used in COPD, combines an inhaled corticosteroid, a long‑acting beta2‑agonist and a long‑acting muscarinic antagonist in a single inhaler.
The approval is based on the Phase III KALOS and LOGOS trials, which showed statistically significant and clinically meaningful improvements in lung function versus dual ICS/LABA therapy, with rapid improvement within five minutes after the first dose. Breztri is a maintenance treatment and does not replace a rescue inhaler.
Asthma affects about 27 million people in the US, and many remain uncontrolled on dual therapies. Breztri is already approved for COPD in 90 countries and was prescribed to more than 6.8 million patients globally in 2025. Regulatory filings for asthma are under review in other major regions including the EU, Japan and China.
AstraZeneca reports that the US Food and Drug Administration has approved Saphnelo (anifrolumab) for subcutaneous self-administration via the once-weekly 120mg Saphnelo Pen autoinjector for adult patients with systemic lupus erythematosus on standard therapy.
The decision is based on the Phase III TULIP-SC trial, where subcutaneous Saphnelo produced a statistically significant and clinically meaningful reduction in disease activity versus placebo, with a safety profile consistent with the existing intravenous formulation. In secondary and exploratory endpoints, 29.0% of patients achieved DORIS remission and 40.1% reached low-level disease activity (LLDAS).
Saphnelo subcutaneous dosing is already approved in the EU and Japan, and more than 40,000 patients worldwide have been treated with Saphnelo. Under an updated agreement, AstraZeneca will pay Bristol-Myers Squibb a mid-teens royalty on US Saphnelo sales.
AstraZeneca PLC announced a change to its Board of Directors. Rene Haas will step down as a Non-Executive Director on 30 April 2026 as he assumes an additional role as Chief Executive Officer of SoftBank Group International alongside his position as CEO of Arm Holdings plc.
The company stated that, under section 430(2B) of the Companies Act 2006, Haas will receive only his non-executive director fees for his time on the Board and no payment for loss of office.
AstraZeneca reported positive interim Phase III results from the global I CAN trial of Ultomiris (ravulizumab) in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression. Ultomiris met the primary interim endpoint, showing a statistically significant and clinically meaningful reduction in proteinuria at week 34, with rapid effects seen as early as week 10.
The trial will continue to week 106 to assess change in estimated glomerular filtration rate (eGFR) and longer-term kidney outcomes. The safety profile was consistent with the known profile of Ultomiris, and AstraZeneca plans to seek accelerated approval in key markets and present full data at a medical meeting.
AstraZeneca reported that its IL-33-targeting biologic tozorakimab met the primary endpoint in the Phase III MIRANDA trial in chronic obstructive pulmonary disease (COPD). The drug produced a statistically significant and clinically meaningful reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and in the overall trial population.
This is the third positive pivotal Phase III trial for tozorakimab in COPD, following the OBERON and TITANIA studies, reinforcing evidence of benefit on top of standard inhaled therapies. Tozorakimab 300mg every two or four weeks was generally well tolerated with a favourable safety profile consistent with earlier trials, and the data will be submitted to regulatory authorities and shared at an upcoming medical meeting.
AstraZeneca PLC reported that all resolutions at its Annual General Meeting held on 9 April 2026 were approved by poll vote. Shareholders received the 2025 accounts, confirmed the 2025 interim dividends, and appointed KPMG LLP as auditor, authorising the directors to set the auditor’s remuneration.
All directors standing for re-election, including Pascal Soriot and Aradhana Sarin, were re-elected, with support generally above 97%, except Marcus Wallenberg who received 83.80% of votes cast. Shareholders approved the remuneration report and renewed the French appendix to the performance share plan.
Authorities were granted to allot shares and to disapply and further disapply pre-emption rights, and to permit the company to purchase its own shares, with 99.81% of votes cast in favour of the share repurchase authority. As at 7 April 2026, issued share capital comprised 1,550,988,781 ordinary shares eligible to vote at the AGM.
AstraZeneca PLC notified the New York Stock Exchange of the voluntary withdrawal of its 0.700% Notes due 2026 from listing and registration on the NYSE. The Exchange certified compliance with Rule 12d2-2 and the issuer complied with the Exchange rules governing voluntary withdrawal.
AstraZeneca reported positive Phase III results from the EMERALD-3 trial in earlier-stage, unresectable hepatocellular carcinoma eligible for embolisation. The regimen combining Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE) achieved a statistically significant and clinically meaningful improvement in progression-free survival versus TACE alone.
At an interim analysis, the combination also showed a trend toward improved overall survival, and a STRIDE regimen plus TACE arm showed strong trends for both progression-free and overall survival, although not yet formally tested. Safety was consistent with known profiles, and the trial will continue to follow overall survival and other secondary endpoints while data are shared with global regulators.
AstraZeneca PLC reported updated share capital and voting rights information. As at 31 March 2026, the company had 1,550,980,823 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, so total voting rights equal this amount.
The company also confirmed the admission to trading on the London Stock Exchange of 491 additional ordinary shares issued under its employee share schemes between 20 and 31 March 2026, under an existing block admission dated 29 January 2021. These new shares are fully fungible with existing ordinary shares.